Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Targeted potassium levels to decrease arrhythmia burden in high risk patients with cardiovascular diseases (POTCAST): Study protocol for a randomized controlled trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Temporal trends in utilization of transcatheter aortic valve replacement and patient characteristics: a nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Atrial fibrillation burden and cognitive decline in elderly patients undergoing continuous monitoring

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Nationwide cardiovascular disease admission rates during a second COVID-19 lockdown

    Research output: Contribution to journalLetterResearchpeer-review

  1. Polygenic risk score for ACE-inhibitor-associated cough based on the discovery of new genetic loci

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Markers of Kidney Function in Early Childhood and Association With Maternal Comorbidity

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Family Screening in Dilated Cardiomyopathy: Prevalence, Incidence, and Potential for Limiting Follow-Up

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Low plasma potassium (p-K) is associated with increased risk of malignant arrhythmia and observational studies indicate protective effects of p-K in the upper reference level. However, randomized clinical studies are needed to document whether actively increasing p-K to high-normal levels is possible and safe and improves cardiovascular outcomes.

OBJECTIVE: To investigate if increased p-K reduces the risk of malignant arrhythmia and all-cause death in high-risk patients with a cardiovascular disease treated with an implantable cardioverter defibrillator (ICD) for primary or secondary preventive causes. Secondly, to investigate whether high-normal p-K levels can be safely reached and maintained using already available medications and potassium-rich dietary guidance.

METHODS: This is a prospective, randomized, and open-labelled study enrolling patient at high-risk of malignant arrhythmias. According to sample size calculations, 1,000 patients will be randomized 1:1 to either an investigational regiment that aims to increase and maintain p-K at high-normal levels (4.5-5.0 mmol/l) or to usual standard of care and followed for an expected four years. The trial will run until a total of 291 events have occurred providing an α=0.05 and 1-β=0.80. The composite primary endpoint includes ventricular tachycardia >125 bpm lasting >30 seconds, any appropriate ICD-therapy, and all-cause mortality. At present, 739 patients have been randomized.

CONCLUSIONS: We present the rationale for the design of the POTCAST trial. The inclusion was initiated 2019 and is expected to be finished 2022. The study will show if easily available treatments to increase p-K may be a new treatment modality to protect against malignant arrythmias.

Original languageEnglish
JournalAmerican Heart Journal
Volume253
Pages (from-to)59-66
Number of pages8
ISSN0002-8703
DOIs
Publication statusPublished - Nov 2022

Bibliographical note

Copyright © 2022. Published by Elsevier Inc.

ID: 79406733